Are metabolites of l-deprenyl (selegiline) useful or harmful? Indications from preclinical research
- PMID: 8988462
- DOI: 10.1007/978-3-7091-7494-4_6
Are metabolites of l-deprenyl (selegiline) useful or harmful? Indications from preclinical research
Abstract
A frequent topic of controversy has been whether metabolism of l-deprenyl (selegiline) to active metabolites is a detriment to clinical use. This paper reviews possible roles of the metabolites of l-deprenyl in producing unwanted adverse side effects or in augmenting or mediating its clinically useful actions. Levels of l-amphetamine and l-methamphetamine likely to be reached, even with excessive intake of l-deprenyl, would be unlikely to produce neurotoxicity and there is no preclinical or clinical evidence of abuse liability of l-deprenyl. In contrast, there is evidence that l-amphetamine and l-methamphetamine have some qualitatively different actions than their d-isomer counterparts on EEG and cognitive functioning which might result in beneficial clinical effects and complement beneficial clinical actions of l-deprenyl itself.
Similar articles
-
Metabolic transformation plays a primary role in the psychostimulant-like discriminative-stimulus effects of selegiline [(R)-(-)-deprenyl].J Pharmacol Exp Ther. 2006 Apr;317(1):387-94. doi: 10.1124/jpet.105.096263. Epub 2005 Dec 13. J Pharmacol Exp Ther. 2006. PMID: 16352699
-
A comparison of drug-seeking behavior maintained by D-amphetamine, L-deprenyl (selegiline), and D-deprenyl under a second-order schedule in squirrel monkeys.Psychopharmacology (Berl). 2006 Jan;183(4):413-21. doi: 10.1007/s00213-005-0200-7. Epub 2005 Nov 15. Psychopharmacology (Berl). 2006. PMID: 16292593 Free PMC article.
-
Gas-chromatographic study on the stereoselectivity of deprenyl metabolism.J Pharm Biomed Anal. 1998 Aug;17(4-5):725-31. doi: 10.1016/s0731-7085(97)00227-6. J Pharm Biomed Anal. 1998. PMID: 9682156
-
Pharmacokinetic aspects of l-deprenyl (selegiline) and its metabolites.Clin Pharmacol Ther. 1994 Dec;56(6 Pt 2):742-9. doi: 10.1038/clpt.1994.204. Clin Pharmacol Ther. 1994. PMID: 7995016 Review.
-
Amphetamine-metabolites of deprenyl involved in protection against neurotoxicity induced by MPTP and 2'-methyl-MPTP.J Neural Transm Suppl. 1994;41:207-19. doi: 10.1007/978-3-7091-9324-2_27. J Neural Transm Suppl. 1994. PMID: 7931228 Review.
Cited by
-
Monoamine-oxidase Type B Inhibitors and Cognitive Functions in Parkinson's Disease: Beyond the Primary Mechanism of Action.Curr Neuropharmacol. 2023;21(5):1214-1223. doi: 10.2174/1570159X20666220905102144. Curr Neuropharmacol. 2023. PMID: 36065929 Free PMC article. Review.
-
A critical appraisal of MAO-B inhibitors in the treatment of Parkinson's disease.J Neural Transm (Vienna). 2022 Jun;129(5-6):723-736. doi: 10.1007/s00702-022-02465-w. Epub 2022 Feb 2. J Neural Transm (Vienna). 2022. PMID: 35107654 Free PMC article. Review.
-
Monoamine Oxidase Inhibitors: From Classic to New Clinical Approaches.Handb Exp Pharmacol. 2021;264:229-259. doi: 10.1007/164_2020_384. Handb Exp Pharmacol. 2021. PMID: 32852645 Review.
-
Efficacy and safety of rasagiline in Chinese patients with early Parkinson's disease: a randomized, double-blind, parallel, placebo-controlled, fixed-dose study.Transl Neurodegener. 2018 Dec 6;7:32. doi: 10.1186/s40035-018-0137-5. eCollection 2018. Transl Neurodegener. 2018. PMID: 30534374 Free PMC article.
-
Inhibitors of MAO-A and MAO-B in Psychiatry and Neurology.Front Pharmacol. 2016 Oct 18;7:340. doi: 10.3389/fphar.2016.00340. eCollection 2016. Front Pharmacol. 2016. PMID: 27803666 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical